当前位置: X-MOL 学术Ann. Hematol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Annals of Hematology ( IF 3.5 ) Pub Date : 2020-02-20 , DOI: 10.1007/s00277-020-03918-6
Mariana Bastos-Oreiro 1, 2 , Ana Muntañola 3 , Carlos Panizo 4 , Eva Gonzalez-Barca 5 , Sonia González de Villambrosia 6 , Raúl Córdoba 7 , Jose Luís Bello López 8 , Pedro González-Sierra 9 , María José Terol 10 , Antonio Gutierrez 11 , Carlos Grande 12 , María José Ramirez 13 , Laura Iserte 14 , Elena Perez 15 , Belén Navarro 16 , Pilar Gomez 17 , Antonio Salar 18 , Hugo Luzardo 19 , Andrés López 20 , Raquel Del Campo 21 , Daniel García-Belmonte 22 , María Jesús Vida 23 , María Infante 24 , Jose Antonio Queizan-Hernandez 25 , Silvana Novelli 26 , Miriam Moreno 27 , Miriam Penarrubia 28 , Joaquín Gómez 29 , Abel Domingo 30 , Eva Donato 31 , María Cruz Viguria 32 , Francisca López 33 , María José Rodriguez 34 , Emilia Pardal 35 , Victor Noriega 36 , Rafael Andreu 37 , Javier Peñalver 38 , Alejandro Martín 39 , Dolores Caballero 39 , Armando López-Guillermo 40
Affiliation  

Lymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological data. Knowledge of local epidemiology is essential to optimise resources, design clinical trials, and identify minority entities. Given there are few published epidemiological data on lymphoma in Spain, the Spanish Lymphoma and Autologous Bone Marrow Transplant Group created the RELINF project. The aim of this project is to determine the frequencies and distribution of lymphoid neoplasms in Spain and to analyse survival. We developed an online platform for the prospective collection of data on newly diagnosed cases of lymphoma in Spain between January 2014 and July 2018; 11,400 patients were registered. Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) were the most frequent lymphomas in our series. Marginal B cell lymphoma frequency was higher than that reported in other studies, representing more than 11% of mature B cell lymphomas. Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) was the most common subtype of T cell lymphoma, and NK/T cell lymphomas were more frequent than expected (5.4% of total). Hodgkin's lymphoma accounted for 12% of lymphoproliferative syndromes. Overall survival was greater than 90% at 2 years for indolent B cell lymphomas, and approximately 60% for DLBCL, somewhat lower than that previously reported. Survival was poor for PTCL-NOS and angioimmunoblastic T cell lymphoma, as expected; however, it was somewhat better than that in other studies for anaplastic large cell anaplastic lymphoma kinase lymphomas. This is the first prospective registry to report the frequencies, distribution, and survival of lymphomas in Spain. The frequencies and survival data we report here are globally consistent with that reported in other Western countries. These updated frequencies and survival statistics are necessary for developing appropriate management strategies for neoplasias in the Spanish population.

中文翻译:

RELINF:西班牙淋巴瘤的前瞻性流行病学登记。GELTAMO集团的一个项目。

淋巴瘤是一大类具有明确特征的异质性肿瘤,这种异质性凸显了流行病学数据的重要性。本地流行病学知识对于优化资源,设计临床试验和确定少数群体至关重要。考虑到西班牙很少有关于淋巴瘤的流行病学数据,西班牙淋巴瘤和自体骨髓移植小组创建了RELINF项目。该项目的目的是确定西班牙淋巴瘤的发生率和分布,并分析其生存率。我们开发了一个在线平台,用于收集2014年1月至2018年7月间西班牙新诊断的淋巴瘤病例的数据;登记了11,400名患者。弥漫性大B细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)是我们系列中最常见的淋巴瘤。边缘性B细胞淋巴瘤发生率高于其他研究报告,占成熟B细胞淋巴瘤的11%以上。周围T细胞淋巴瘤未另作说明(PTCL-NOS)是T细胞淋巴瘤的最常见亚型,NK / T细胞淋巴瘤的发生率高于预期(占总数的5.4%)。霍奇金淋巴瘤占淋巴增生综合征的12%。惰性B细胞淋巴瘤的2年总生存率大于90%,而DLBCL约为60%,略低于先前报道的水平。如预期的那样,PTCL-NOS和血管免疫母细胞性T细胞淋巴瘤的生存期较差;然而,对于间变性大细胞间变性淋巴瘤激酶淋巴瘤而言,它比其他研究更好。这是西班牙第一个报告淋巴瘤发生率,分布和生存率的前瞻性注册机构。我们在此报告的频率和生存数据与其他西方国家在全球范围内一致。这些更新的频率和生存统计数据对于制定西班牙人群瘤形成的适当治疗策略是必要的。
更新日期:2020-02-20
down
wechat
bug